326914-13-0 (((Z)-N-[2-(Diethylamino)ethyl]-5-(5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide)

结构式：

(Z)-N-[2-(Diethylamino)ethyl]-5-(5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxamideMOL文件

CAS号：

326914-13-0

英文名称：

(Z)-N-[2-(Diethylamino)ethyl]-5-(5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide

分子式：

C₂₂H₂₇FN₄O₂

分子量：

398.473788499832

(Z)-N-[2-(Diethylamino)ethyl]-5-(5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide(326914-13-0)名称与标识符

名称

英文别名：

(Z)-N-[2-(Diethylamino)ethyl]-5-(5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide;PNU-290940AD;SU-010398;SU-011248 L-malate salt;Sutent;N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-indolin-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide;1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-,(2S)- hydroxybutanedioate (1:1);

标识符

InChIKey：

WINHZLLDWRZWRT-ATVHPVEESA-N

Inchi：

1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-

SMILES：

O=C(NCCN(CC)CC)C1C(C)=C(/C=C2/C3C=C(C=CC=3NC/2=O)F)NC=1C

(Z)-N-[2-(Diethylamino)ethyl]-5-(5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide(326914-13-0)物化性质

实验特性

PSA : 77.23

计算特性

精确分子量 : 398.21201

(Z)-N-[2-(Diethylamino)ethyl]-5-(5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide(326914-13-0)国际标准相关数据

EINECS：

680-666-2

(Z)-N-[2-(Diethylamino)ethyl]-5-(5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide(326914-13-0)相关文献

1. Novel quinoxaline-3-propanamides as VGFR-2 inhibitors and apoptosis inducers
Magda M. F. Ismail,Taghreed Z. Shawer,Rabab S. Ibrahim,Mostafa S. Abusaif,Mona M. Kamal,Rasha M. Allam,Yousry A. Ammar RSC Adv. 2023 13 31908
2. FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms
Baku Acharya,Debasmita Saha,Daniel Armstrong,Naga Rajiv Lakkaniga,Brendan Frett RSC Med. Chem. 2022 13 798
3. Highly fluorescent nitrogen-doped graphene quantum dots as a green, economical and facile sensor for the determination of sunitinib in real samples
H. Mahmood Kashani,T. Madrakian,A. Afkhami New J. Chem. 2017 41 6875
4. 5-Hydroxy-7-azaindolin-2-one, a novel hybrid of pyridinol and sunitinib: design, synthesis and cytotoxicity against cancer cells
Sajita Shah,Chaemin Lee,Hyukjae Choi,Jaya Gautam,Hyeonjin Jang,Geum Jin Kim,Yu-Jeong Lee,Chhabi Lal Chaudhary,Sang Won Park,Tae-gyu Nam,Jung-Ae Kim,Byeong-Seon Jeong Org. Biomol. Chem. 2016 14 4829
5. The programmed site-specific delivery of the angiostatin sunitinib and chemotherapeutic paclitaxel for highly efficient tumor treatment
Jin He,Hong Xiao,Bo Li,Yuan Peng,Xiaoxia Li,Yong Wang,Grazyna Adamus,Marek Kowalczuk,Xintao Shuai J. Mater. Chem. B 2019 7 4953
6. Functional block copolymer micelles based on poly (jasmine lactone) for improving the loading efficiency of weakly basic drugs
Aliaa Ali,Rajendra Bhadane,Afshin Ansari Asl,Carl-Eric Wilén,Outi Salo-Ahen,Jessica M. Rosenholm,Kuldeep K. Bansal RSC Adv. 2022 12 26763
7. Computational analysis revealing that K634 and T681 mutations modulate the 3D-structure of PDGFR-β and lead to sunitinib resistance
Vishal Nemaysh,Pratibha Mehta Luthra RSC Adv. 2017 7 37612
8. Novel pyrazolo[3,4-d]pyrimidine derivatives: design, synthesis, anticancer evaluation, VEGFR-2 inhibition, and antiangiogenic activity
Ahmed M. Abdelhamed,Rasha A. Hassan,Hanan H. Kadry,Amira A. Helwa RSC Med. Chem. 2023 14 2640
9. Mapping lung tumor cell drug responses as a function of matrix context and genotype using cell microarrays
Kerim B. Kaylan,Stefan D. Gentile,Lauren E. Milling,Kaustubh N. Bhinge,Farhad Kosari,Gregory H. Underhill Integr. Biol. 2016 8 1221
10. Assessment of paper tip angular position, carryover, matrix effects and dried blood spot storage effect on paper spray mass spectrometry
John Takyi-Williams,Wenying Jian,Yang Wang,Kai Tang,Haiqing Gong,Chuan-Fa Liu Anal. Methods 2020 12 747

356068-94-5(Z)-5-(5-氟-2-氧代-2,3-二氢-1H-吲哚-3-亚基甲基)-2,4-二甲基-N-[2-(1-吡咯烷基)乙基]-1H-吡咯-3-甲酰胺) 1196450-91-5(1H-吡咯-3-甲酰胺，N-[2-（二乙氨基）乙基]-5-) 326914-17-4(舒尼替尼杂质) 1186651-51-3(5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide) 356068-97-8(N-去乙基舒尼替尼) 79574-61-1(1-(2-Fluoro-3-pyridinyl)ethanol) 796856-41-2(1-(2,6-二氯吡啶-4-基)哌嗪) 790667-68-4(4-(3-氨基苯氧基)哌啶-1-羧酸叔丁酯)

960化工网为您提供(Z)-N-[2-(Diethylamino)ethyl]-5-(5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide专业化合物百科信息，包括中文名，英文名，分子式，分子量，以及该化合物的CasNo.326914-13-0,相关理化性质;并提供了优质生产厂家信息包括厂家名称和联系方式等。 WAP版:326914-13-0 国际站:326914-13-0